{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MAP-I&page=2",
    "query": {
      "intervention": "MAP-I",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MAP-I&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T02:42:06.345Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02926638",
      "title": "Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "MET Positive",
        "Recurrent Squamous Cell Lung Carcinoma",
        "Stage IV Squamous Cell Lung Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Erlotinib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Rilotumumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2014-06-16",
      "completion_date": "2016-10-12",
      "has_results": true,
      "last_update_posted_date": "2020-03-19",
      "last_synced_at": "2026-09-25T02:42:06.345Z",
      "location_count": 627,
      "location_summary": "Jonesboro, Arkansas • Little Rock, Arkansas • Anaheim, California + 402 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Antioch",
          "state": "California"
        },
        {
          "city": "Auburn",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02926638"
    },
    {
      "nct_id": "NCT03752736",
      "title": "Sun Safety Skills for Elementary School Students",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sunburn",
        "Skin Cancer Prevention"
      ],
      "interventions": [
        {
          "name": "\"I wear sunscreen everyday\" song-based video",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "7 Years",
        "sex": "ALL",
        "summary": "5 Years to 7 Years"
      },
      "enrollment_count": 96,
      "start_date": "2019-02-25",
      "completion_date": "2019-05-23",
      "has_results": false,
      "last_update_posted_date": "2019-08-13",
      "last_synced_at": "2026-09-25T02:42:06.345Z",
      "location_count": 1,
      "location_summary": "Cupertino, California",
      "locations": [
        {
          "city": "Cupertino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03752736"
    },
    {
      "nct_id": "NCT02965378",
      "title": "Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "FGFR1 Gene Amplification",
        "FGFR1 Gene Mutation",
        "FGFR2 Gene Amplification",
        "FGFR2 Gene Mutation",
        "FGFR3 Gene Amplification",
        "FGFR3 Gene Mutation",
        "Recurrent Squamous Cell Lung Carcinoma",
        "Stage IV Squamous Cell Lung Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "FGFR Inhibitor AZD4547",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "25 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2014-10",
      "completion_date": "2019-10",
      "has_results": true,
      "last_update_posted_date": "2021-05-27",
      "last_synced_at": "2026-09-25T02:42:06.345Z",
      "location_count": 1083,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 672 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02965378"
    },
    {
      "nct_id": "NCT02439346",
      "title": "Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Medical Oncology"
      ],
      "interventions": [
        {
          "name": "BAY1143269 tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2015-06-15",
      "completion_date": "2017-04-24",
      "has_results": false,
      "last_update_posted_date": "2018-03-07",
      "last_synced_at": "2026-09-25T02:42:06.345Z",
      "location_count": 3,
      "location_summary": "Dallas, Texas • Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02439346"
    },
    {
      "nct_id": "NCT01906307",
      "title": "A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatorenal Syndrome Type I and Type II"
      ],
      "interventions": [
        {
          "name": "LJPC-501",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "La Jolla Pharmaceutical Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2014-03",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2016-03-03",
      "last_synced_at": "2026-09-25T02:42:06.345Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01906307"
    },
    {
      "nct_id": "NCT05014984",
      "title": "WOOP VA: Promoting Weight Management in Primary Care",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "mental contrasting with implementation intentions",
          "type": "BEHAVIORAL"
        },
        {
          "name": "telephone-delivered, telehealth-delivered, and or in-person MOVE! or TeleMOVE!",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Information About Diet, Physical Activity, and Weight Management (Baseline Visit - 10 minutes): All",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Telephone MCII Check-ins (30 minutes at 3 days, 4 weeks, and 2 months after baseline visit)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 405,
      "start_date": "2022-02-15",
      "completion_date": "2026-02-11",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-09-25T02:42:06.345Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05014984"
    },
    {
      "nct_id": "NCT00624650",
      "title": "Hemodynamics and Extravascular Lung Water in Acute Lung Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lung Injury"
      ],
      "interventions": [
        {
          "name": "Diuresis (furosemide) part I",
          "type": "DRUG"
        },
        {
          "name": "Fluid Bolus (crystalloid or albumin)",
          "type": "OTHER"
        },
        {
          "name": "Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)",
          "type": "DRUG"
        },
        {
          "name": "Dobutamine",
          "type": "DRUG"
        },
        {
          "name": "Concentrate all drips and nutrition",
          "type": "OTHER"
        },
        {
          "name": "Diuresis (furosemide) part II",
          "type": "DRUG"
        },
        {
          "name": "Dialysis",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2008-02",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2019-09-10",
      "last_synced_at": "2026-09-25T02:42:06.345Z",
      "location_count": 3,
      "location_summary": "Clackamas, Oregon • Portland, Oregon",
      "locations": [
        {
          "city": "Clackamas",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00624650"
    },
    {
      "nct_id": "NCT02785952",
      "title": "Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Recurrent Squamous Cell Lung Carcinoma",
        "Stage IV Squamous Cell Lung Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 275,
      "start_date": "2015-12-29",
      "completion_date": "2027-04-01",
      "has_results": true,
      "last_update_posted_date": "2026-06-09",
      "last_synced_at": "2026-09-25T02:42:06.345Z",
      "location_count": 1201,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 735 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02785952"
    },
    {
      "nct_id": "NCT00895986",
      "title": "Using Conversation Maps to Reinforce Self-Care",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Conversation Maps Diabetes Education",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Heart Healthy Living Diabetes Education",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Joslin Diabetes Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "25 Years to 75 Years"
      },
      "enrollment_count": 134,
      "start_date": "2008-12",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2012-10-18",
      "last_synced_at": "2026-09-25T02:42:06.345Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00895986"
    },
    {
      "nct_id": "NCT03511976",
      "title": "Adaptive Response to Intervention (RTI) for Students With ADHD",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention Deficit Disorder With Hyperactivity"
      ],
      "interventions": [
        {
          "name": "Tier 1 Classroom Management",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Daily Report Card (DRC)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Enhanced DRC (DRC-E)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Stimulant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "Florida International University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 0,
      "start_date": "2018-05-14",
      "completion_date": "2023-10-21",
      "has_results": false,
      "last_update_posted_date": "2025-08-07",
      "last_synced_at": "2026-09-25T02:42:06.345Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Buffalo, New York",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03511976"
    }
  ]
}